BioAtla Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
41
- Stock Symbol
-
BCAB
- Share Price
-
$1.55
- (As of Friday Closing)
BioAtla General Information
Description
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
Contact Information
Website
www.bioatla.comCorporate Office
- 11085 Torreyana Road
- San Diego, CA 92121
- United States
Corporate Office
- 11085 Torreyana Road
- San Diego, CA 92121
- United States
BioAtla Stock Performance
As of 20-Nov-2026, BioAtla’s stock price is $1.55. Its current market cap is $2.58M with 1.67M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.55 | $1.29 | $1.07 - $59.50 | $2.58M | 1.67M | 39.7K | -$16.56 |
BioAtla Financials Summary
As of 30-Sep-2026, BioAtla has a trailing 12-month revenue of $8.75M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,485 | 31,237 | (20,961) | 128,558 |
| Revenue | 8,750 | 2,000 | 11,000 | 0 |
| EBITDA | (23,572) | (60,077) | (72,220) | (128,553) |
| Net Income | (23,573) | (59,607) | (69,776) | (123,462) |
| Total Assets | 1,109 | 13,828 | 52,422 | 119,658 |
| Total Debt | 5,874 | 6,200 | 836 | 2,460 |
BioAtla Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioAtla Comparisons
Industry
Financing
Details
BioAtla Competitors (61)
One of BioAtla’s 61 competitors is Outlook Therapeutics, a Formerly VC-backed company based in Iselin, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Outlook Therapeutics | Formerly VC-backed | Iselin, NJ | ||||
| Molecular Partners | Formerly VC-backed | Zurich, Switzerland | ||||
| Zymeworks | Formerly VC-backed | Vancouver, Canada | ||||
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| AC Immune | Formerly VC-backed | Lausanne, Switzerland |
BioAtla Patents
BioAtla Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026169912-A1 | Conditionally active antigen binding polypeptides to a b7-h3 (cd276) antigen, compositions, and methods of use thereof | Pending | 06-Feb-2025 | ||
| WO-2025198961-A1 | Methods and pharmaceutical composition for the treatment of adenoid cystic carcinoma | Pending | 19-Mar-2024 | ||
| AU-2024267583-A1 | Protein therapeutics for treatment of senescent cells | Pending | 07-May-2023 | ||
| EP-4709912-A1 | Protein therapeutics for treatment of senescent cells | Pending | 07-May-2023 | ||
| WO-2024232976-A1 | Protein therapeutics for treatment of senescent cells | Inactive | 07-May-2023 | C07K16/18 |
BioAtla Signals
BioAtla Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BioAtla ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.78 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
BioAtla FAQs
-
When was BioAtla founded?
BioAtla was founded in 2007.
-
Where is BioAtla headquartered?
BioAtla is headquartered in San Diego, CA.
-
What is the size of BioAtla?
BioAtla has 41 total employees.
-
What industry is BioAtla in?
BioAtla’s primary industry is Drug Discovery.
-
Is BioAtla a private or public company?
BioAtla is a Public company.
-
What is BioAtla’s stock symbol?
The ticker symbol for BioAtla is BCAB.
-
What is the current stock price of BioAtla?
As of 20-Nov-2026 the stock price of BioAtla is $1.55.
-
What is the current market cap of BioAtla?
The current market capitalization of BioAtla is $2.58M.
-
What is BioAtla’s current revenue?
The trailing twelve month revenue for BioAtla is $8.75M.
-
Who are BioAtla’s competitors?
Outlook Therapeutics, Molecular Partners, Zymeworks, Inhibrx, and AC Immune are some of the 61 competitors of BioAtla.
-
What is BioAtla’s annual earnings per share (EPS)?
BioAtla’s EPS for 12 months was -$16.56.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process